SIS 105
Alternative Names: SIS-105Latest Information Update: 03 Mar 2023
At a glance
- Originator SiSaf
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 18 Jan 2023 Preclinical trials in Eye disorders in United Kingdom (Ophthalmic)